DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Kubitza D, Becka M, Zuehlsdorf M. et al.
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects.
J Clin Pharmacol 2007;
47: 218-226.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.